Standout Papers

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis 2017 2026 2020 2023 412
  1. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis (2017)
    Philip J. Mease, Stephen Hall et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 73 standout
Sub-graph 1 of 20

Citing Papers

Atopic dermatitis
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
14 intermediate papers

Works of Daniela Graham being referenced

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
2018
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
2017 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Daniela Graham 536 428 313 20 837
A. Accardo-Palumbo 375 325 233 29 799
Lynette Peddle 402 495 217 20 818
Elizabeth McDermott 157 417 183 18 872
M. McIlraith 217 358 128 17 653
Naonobu Sugiyama 464 356 195 33 846
Nasser Khan 682 266 334 27 953
Ceara AE Walsh 385 194 154 11 706
Alessandra Cannizzaro 360 389 160 15 712
Martin Birkhofer 122 364 138 20 793
Stefania Sacco 489 257 171 20 936

All Works

Loading papers...

Rankless by CCL
2026